Literature DB >> 26704277

[Urinary diversion in elderly patients].

M Spahn1, S Boxler2.   

Abstract

BACKGROUND: Bladder cancer represents one of the ten most prevalent cancers worldwide. More than 400,000 people worldwide are newly diagnosed every year. Within 2 years after diagnosis, 80% of patients with muscle invasive bladder cancer without treatment die.
METHODS: The aggressive local surgical approach with a cystectomy is the therapy of choice. The median age of patients with de novo bladder cancer is 70 years. Thus bladder cancer is a cancer of the elderly. For demographical reasons, the number of eldery patients undergoing radical cystectomy will rise in the next few years. The type of urinary diversion is a major factor influencing perioperative morbidity and quality of life in these patients. Incontinent urinary diversions are preferentially used in daily practice.
CONCLUSIONS: There are only a few contraindications for orthotopic neobladder; however, age alone is not a contraindication. Patient selection and a nerve sparing approach are crucial in men and women to achieve excellent functional results with orthotopic neobladder in elderly patients.

Entities:  

Keywords:  Cystectomy; Ileocecal pouch; Neobladder, orthotopic; Pouch, catheterizable; Urinary bladder neoplasms

Mesh:

Year:  2015        PMID: 26704277     DOI: 10.1007/s00120-015-4010-1

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  19 in total

1.  A brief clinical instrument to classify frailty in elderly people.

Authors:  K Rockwood; K Stadnyk; C MacKnight; I McDowell; R Hébert; D B Hogan
Journal:  Lancet       Date:  1999-01-16       Impact factor: 79.321

2.  A simple device in the prevention of recurrent appendico-umbilical stenosis.

Authors:  U Köhl; E W Gerharz; K Weingärtner; H Riedmiller
Journal:  Br J Urol       Date:  1996-04

3.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.

Authors:  M E Charlson; P Pompei; K L Ales; C R MacKenzie
Journal:  J Chronic Dis       Date:  1987

4.  Orthotopic ileal bladder substitution in women: factors influencing urinary incontinence and hypercontinence.

Authors:  Tobias Gross; Susan D Meierhans Ruf; Claudia Meissner; Katharina Ochsner; Urs E Studer
Journal:  Eur Urol       Date:  2015-05-27       Impact factor: 20.096

Review 5.  Radical cystectomy for invasive bladder cancer: contemporary results and remaining controversies.

Authors:  J E Gschwend; W R Fair; J Vieweg
Journal:  Eur Urol       Date:  2000-08       Impact factor: 20.096

6.  Radical cystectomy for bladder cancer today--a homogeneous series without neoadjuvant therapy.

Authors:  Stephan Madersbacher; Werner Hochreiter; Fiona Burkhard; George N Thalmann; Hansjörg Danuser; Regula Markwalder; Urs E Studer
Journal:  J Clin Oncol       Date:  2003-02-15       Impact factor: 44.544

Review 7.  A critical analysis of orthotopic bladder substitutes in adult patients with bladder cancer: is there a perfect solution?

Authors:  Wassim Kassouf; Richard E Hautmann; Bernard H Bochner; Seth P Lerner; Renzo Colombo; Alexandre Zlotta; Urs E Studer
Journal:  Eur Urol       Date:  2010-05-22       Impact factor: 20.096

8.  Radical cystectomy in the elderly: comparison of clincal outcomes between younger and older patients.

Authors:  Peter E Clark; John P Stein; Susan G Groshen; Jie Cai; Gus Miranda; Gary Lieskovsky; Donald G Skinner
Journal:  Cancer       Date:  2005-07-01       Impact factor: 6.860

9.  Morbidity and quality of life in elderly patients receiving ileal conduit or orthotopic neobladder after radical cystectomy for invasive bladder cancer.

Authors:  Filippo Sogni; Maurizio Brausi; Bruno Frea; Carlo Martinengo; Fabrizio Faggiano; Alessandro Tizzani; Paolo Gontero
Journal:  Urology       Date:  2008-03-20       Impact factor: 2.649

Review 10.  Complications following radical cystectomy for bladder cancer in the elderly.

Authors:  Michael Froehner; Maurizio A Brausi; Harry W Herr; Giovanni Muto; Urs E Studer
Journal:  Eur Urol       Date:  2009-05-18       Impact factor: 20.096

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.